Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corgenix seeks US OK for AspirinWorks:

This article was originally published in Clinica

Executive Summary

Denver, Colorado company Corgenix Medical has submitted to the US FDA a 510(k) application to market its urine test kit for assessing the effectiveness of aspirin when used as a preventive therapy for cardiovascular disease. The AspirinWorks kit, a quantitative ELISA test that determines levels of 11-dehydro thromboxane B2, measures an individual's response to aspirin dose and allows physicians to adjust the dose or recommend alternative therapy, said the firm. The company added that recent reports indicate that up to 25% of individuals may be non-responsive to aspirin's benefits, and are over three times more likely to die from heart disease. The kit, which was launched outside the US a few weeks ago, was developed jointly by Corgenix, fellow Denver firm Creative Clinical Concepts and Ann Arbor, Michigan-based Cayman Chemical Company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel